Drug Trial Radar · NCT06481215
A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Mar 11, 2022
Primary completion
Sep 4, 2022
Study completion Dec 20, 2022
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized open comparative parallel group study of the safety and pharmacokinetics of GNR-068 and Stelara® in healthy volunteers. Participants received a single subcutaneous dose of ustekinumab 45 mg. The follow up period was 84 days.
Conditions
- Healthy Volunteers
Interventions
GNR-068Biological
The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
Stelara®Biological
The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: Area under the plasma concentration versus time curve (AUC)Time frame: Day 84
- Pharmacokinetics: Peak Plasma Concentration (Cmax)Time frame: Day 84
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department"
Moscow, Russia
Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental University named after A.I. Evdokimov" of the Ministry of Health of the Russian Federation
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.